Factors associated of long-term retention rate of Janus kinase inhibitors in a multi-failure rheumatoid arthritis population
Authors' conclusion
In conclusion, our study supports the clinical effectiveness of JAKi in RA, even in the multi-failure subgroup of patients, where the risk/benefit ratio overcomes the safety risk.
Study context
- Population
- Consecutive rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKi), incl. difficult-to-treat subgroups
- Participants
- 330 patients
- Outcome
- Retention rate and causes of discontinuation of JAKi
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
Factors associated with JAKi retention
- Anticitrullinated peptide antibodies (ACPA) and combination therapy with csDMARDs associated with longer drug persistence
- ACPA independently associated with higher JAKi retention rate in difficult-to-treat subgroup
Observational data: associations, not effects.
Further findings
Cohort characteristics
- Failed ≥2 bDMARDs
- 50.3%
- Risk factors for JAKi use
- 75.5%
- Older than 65 years
- 41.5%
- Had smoked
- 37.6%
- Increased cardiovascular or cancer risk
- 48.8%
Original publication
Factors associated of long-term retention rate of Janus kinase inhibitors in a multi-failure rheumatoid arthritis population. Clin Exp Rheumatol. Published 31 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →